KalVista Pharmaceuticals Initiates First European Launch of EKTERLY® for Hereditary Angioedema in Germany Following EU Approval
Tuesday, November 11, 2025
KalVista Pharmaceuticals, Inc., with operational headquarters in Salisbury, England, has issued a significant update on November 11, 2025, marking a strategic achievement for European rare disease treatment. Having secured European Commission (EC) and Swiss Agency for Therapeutic Products (Swissmedic) regulatory approvals in September 2025 for EKTERLY® (sebetralstat), KalVista initiated its first European commercial launch in Germany during October, supported by robust demand and proactive physician engagement. This development positions EKTERLY as the first and only oral on-demand treatment available for hereditary angioedema (HAE) across all 27 EU member states, as well as in Iceland, Liechtenstein, and Norway.
EKTERLY targets acute HAE attacks in adults and adolescents aged 12 years and older. The German launch is backed by initial patient shipments, engaging prescribers rapidly and facilitating improved treatment accessibility. According to CEO Ben Palleiko, ongoing positive feedback and increasing repeat prescriptions underscore the clinical and commercial value of EKTERLY in Europe.
KalVista’s approach encompasses strategic market entry and sustainable growth across multiple regions. Prior to the European rollout, EKTERLY underwent a successful US commercial launch in July 2025, accumulating 937 patient start forms and activating 423 distinct prescribers by October 31, 2025. This momentum provided a template for the European execution, ensuring regulatory compliance and strong operational coordination. The EC approval signifies continent-wide access, meeting unmet needs for oral, rapid-acting therapies for HAE, where intravenous or injectable alternatives have traditionally predominated.
The recent German launch amplifies KalVista’s broader commercialization strategy, leveraging new $144 million convertible note financing to ensure resource availability for continued expansion. The company emphasizes its ambition to make EKTERLY a global product, evidenced by concurrent launches and regulatory advances in Australia and Switzerland. The pan-European approval not only enhances patient options but also sets the stage for further expansion into other regulated markets under mutual recognition pathways.
Central to KalVista’s business model is the integration of commercial operations with ongoing clinical research. At the 2025 ACAAI Annual Scientific Meeting, interim data from the KONFIDENT-KID trial revealed that pediatric administration of sebetralstat enabled early, safe intervention with a median dosing time of 30 minutes and symptom relief within 1.5 hours, expanding the potential market base and supporting the product’s therapeutic profile. This clinical progress strengthens the company’s pipeline and evidences a responsive, data-driven commercialization process.
Germany, as a leading European pharma market, serves as a benchmark for further launches in the region. Initial demand is reported as strong, reflecting both clinical need and market receptivity. The value proposition for payers and prescribers resides in EKTERLY’s oral, rapid-action profile that simplifies administration, improves patient quality of life, and potentially reduces overall health system burden associated with HAE management. KalVista’s direct partnership model for distribution and patient support in Germany exemplifies modern commercialization practices in the biopharma sector.
Looking ahead, KalVista’s recent European success underpins its global launch strategy, reinforcing operational confidence and investor appeal. The expansion into Germany showcases how targeted regulatory navigation, coordinated supply chain management, and clinician engagement can drive adoption of innovative therapies. For European pharma executives and stakeholders, KalVista’s methods offer valuable insights into strategic market entry, regulatory harmonization, and patient-centric product launches for rare diseases.
As KalVista continues to track performance, gather post-market data, and scale operations, the first European launch of EKTERLY in Germany stands as a milestone for the region’s orphan disease therapeutic landscape and a potential template for subsequent country launches. This event is directly relevant to European pharma leaders monitoring new drug approvals, evolving commercialization frameworks, market access strategies, and rare disease treatment advancements.
